Guo Jiao, Jia Xiaoying, Liu Yang, Wang Shaobo, Cao Junyuan, Zhang Bo, Xiao Gengfu, Wang Wei
State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.
University of the Chinese Academy of Sciences, 100049, Beijing, China.
Commun Biol. 2020 Jul 15;3(1):380. doi: 10.1038/s42003-020-1109-8.
Zika virus (ZIKV) is an infectious disease that has become an important concern worldwide, it associates with neurological disorders and congenital malformations in adults, also leading to fetal intrauterine growth restriction and microcephaly during pregnancy. However, there are currently no approved vaccines or specific antiviral drugs for preventing or treating ZIKV infection. Here, we show that two FDA-approved Na/K-ATPase inhibitors, ouabain and digoxin, can block ZIKV infection at the replication stage by targeting Na/K-ATPase. Furthermore, ouabain reduced the viral burden of ZIKV in adult mice, penetrated the placental barrier to enter fetal tissues, and protected fetal mice from ZIKV infection-induced microcephaly in a pregnant mouse model. Thus, ouabain has therapeutic potential for ZIKV.
寨卡病毒（ZIKV）是一种已成为全球重要关注点的传染病，它与成人的神经紊乱和先天性畸形有关，在孕期还会导致胎儿宫内生长受限和小头畸形。然而，目前尚无获批用于预防或治疗寨卡病毒感染的疫苗或特异性抗病毒药物。在此，我们表明两种经美国食品药品监督管理局（FDA）批准的钠钾ATP酶抑制剂，哇巴因和地高辛，可通过靶向钠钾ATP酶在复制阶段阻断寨卡病毒感染。此外，哇巴因降低了成年小鼠体内寨卡病毒的病毒载量，穿透胎盘屏障进入胎儿组织，并在孕鼠模型中保护胎鼠免受寨卡病毒感染所致的小头畸形。因此，哇巴因对寨卡病毒具有治疗潜力。
